Pages that link to "Q44534289"
Jump to navigation
Jump to search
The following pages link to The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl cells sensitive and resistant to STI571. (Q44534289):
Displaying 50 items.
- Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress (Q23918915) (← links)
- Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy (Q24814325) (← links)
- TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. (Q27851687) (← links)
- 6-Shogaol induces apoptosis in human leukemia cells through a process involving caspase-mediated cleavage of eIF2α (Q28394859) (← links)
- Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors (Q28474489) (← links)
- Anticancer activities of histone deacetylase inhibitors (Q29616624) (← links)
- Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer (Q30430515) (← links)
- Leukemia-targeting ligands isolated from phage-display peptide libraries. (Q33270272) (← links)
- Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma (Q33388541) (← links)
- A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors (Q33410836) (← links)
- Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. (Q33482818) (← links)
- A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance (Q33767209) (← links)
- Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation (Q33863049) (← links)
- Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights (Q33983255) (← links)
- The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors (Q34218976) (← links)
- Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer (Q34240470) (← links)
- Blastic phase of chronic myelogenous leukemia (Q34514042) (← links)
- Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study (Q34632964) (← links)
- Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases (Q34795203) (← links)
- Bortezomib treatment causes remission in a Ph ALL patient and reveals FoxO as a theranostic marker (Q34929425) (← links)
- Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. (Q35025461) (← links)
- Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors (Q35133399) (← links)
- Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma (Q35186682) (← links)
- Histone deacetylase inhibitors in clinical development (Q35609717) (← links)
- Targeted therapies for ER /HER2- metastatic breast cancer (Q35658860) (← links)
- Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies (Q35741937) (← links)
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias (Q35750919) (← links)
- A closer look at specific therapeutic strategies in leukemia (Q35821017) (← links)
- Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease (Q35828737) (← links)
- Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance (Q35847734) (← links)
- The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism (Q35848514) (← links)
- NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells (Q35850681) (← links)
- Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance (Q35850687) (← links)
- Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein (Q35882968) (← links)
- Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects (Q35939690) (← links)
- Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim (Q35982670) (← links)
- Proteasome inhibitors in mantle cell lymphoma (Q36028745) (← links)
- The transcription factor NF-kappaB as drug target (Q36105771) (← links)
- Emerging drugs for the treatment of myelodysplastic syndrome (Q36219655) (← links)
- Histone deacetylase inhibitors: insights into mechanisms of lethality (Q36219726) (← links)
- New agents in the treatment of childhood leukemias and myelodysplastic syndromes (Q36284664) (← links)
- FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis (Q36334327) (← links)
- Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma (Q36407209) (← links)
- A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916) (Q36438027) (← links)
- Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. (Q36529784) (← links)
- Targeting epigenetic abnormalities with histone deacetylase inhibitors (Q36529933) (← links)
- Redox control of leukemia: from molecular mechanisms to therapeutic opportunities (Q36646486) (← links)
- Proteasome inhibitors: antitumor effects and beyond (Q36649676) (← links)
- Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib (Q36782473) (← links)
- Development of histone deacetylase inhibitors for cancer treatment (Q36788512) (← links)